Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation
Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation
Recruiting · NCT07626281 · Registry updated 2026-10-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Assessment of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a New Formulation of Inclisiran Containing Polysorbate 80 Compared to the Currently Marketed Formulation | Inclisiran Formulation | Recruiting | Phase 1 | 2026-10-05 | NCT07626281 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Novartis Pharmaceuticals | 432 |
6 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cardiovasular Renal Metabolism | San Antonio | United States | 1 |
| ICON Early Clin Service San Antonio | San Antonio | United States | 1 |
| ICON Early Clin Services Lenexa | Lenexa | United States | 1 |
| ICON Early Clinical Services SLC | Salt Lake City | United States | 1 |
| Lenexa Research Unit | Lenexa | United States | 1 |
| Salt Lake City Research Unit | Salt Lake City | United States | 1 |